CN106872634A - Facial paralysis quality determining method just scattered again - Google Patents
Facial paralysis quality determining method just scattered again Download PDFInfo
- Publication number
- CN106872634A CN106872634A CN201710132017.6A CN201710132017A CN106872634A CN 106872634 A CN106872634 A CN 106872634A CN 201710132017 A CN201710132017 A CN 201710132017A CN 106872634 A CN106872634 A CN 106872634A
- Authority
- CN
- China
- Prior art keywords
- solution
- facial paralysis
- thin
- medicinal material
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 208000004929 Facial Paralysis Diseases 0.000 title claims abstract description 49
- 208000036826 VIIth nerve paralysis Diseases 0.000 title claims abstract description 43
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 23
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 20
- 240000006688 Telosma cordata Species 0.000 claims abstract description 18
- 235000017352 Telosma cordata Nutrition 0.000 claims abstract description 18
- 241000218378 Magnolia Species 0.000 claims abstract description 17
- 238000002474 experimental method Methods 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 17
- 238000003556 assay Methods 0.000 claims abstract description 10
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims abstract description 10
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims abstract description 8
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000007689 inspection Methods 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 7
- 230000000813 microbial effect Effects 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 103
- 238000012360 testing method Methods 0.000 claims description 87
- 239000000463 material Substances 0.000 claims description 51
- 239000013642 negative control Substances 0.000 claims description 33
- 239000013558 reference substance Substances 0.000 claims description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 23
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 21
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 21
- 229940116229 borneol Drugs 0.000 claims description 21
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 21
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 19
- 238000004809 thin layer chromatography Methods 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 16
- 238000004587 chromatography analysis Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 13
- 239000000741 silica gel Substances 0.000 claims description 13
- 229910002027 silica gel Inorganic materials 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000007747 plating Methods 0.000 claims description 11
- 229930182494 ginsenoside Natural products 0.000 claims description 10
- 229940089161 ginsenoside Drugs 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 238000011161 development Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 4
- NJUISRMVIKYYCN-UHFFFAOYSA-N acetic acid;chloroform;methanol;hydrate Chemical compound O.OC.CC(O)=O.ClC(Cl)Cl NJUISRMVIKYYCN-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 240000004580 Magnolia hypoleuca Species 0.000 claims description 2
- PQPKPCPUSAPERC-UHFFFAOYSA-N ethyl acetate;formic acid;hexane Chemical compound OC=O.CCCCCC.CCOC(C)=O PQPKPCPUSAPERC-UHFFFAOYSA-N 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000012850 discrimination method Methods 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 238000002360 preparation method Methods 0.000 abstract description 12
- 238000012372 quality testing Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 11
- 238000011084 recovery Methods 0.000 description 8
- 241000235342 Saccharomycetes Species 0.000 description 7
- 241001148470 aerobic bacillus Species 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000004088 simulation Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001467 acupuncture Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 210000000256 facial nerve Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 150000001637 borneol derivatives Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- RZWGTXHSYZGXKF-UHFFFAOYSA-N 2-(2-methylphenyl)acetic acid Chemical compound CC1=CC=CC=C1CC(O)=O RZWGTXHSYZGXKF-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000303379 Styrax officinalis Species 0.000 description 1
- 235000001361 Styrax officinalis Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000014337 facial nerve disease Diseases 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical group [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/10—Enterobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/14—Streptococcus; Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/02—Investigating particle size or size distribution
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the quality determining method that a kind of facial paralysis is just scattered again, facial paralysis quality determining method just scattered again includes following several：(1) proterties：Khaki powder；Gas is pungent, bitter；(2) differentiate：Including pseudo-ginseng, prepared RADIX ET RHIZOMA RHEI, Chinese violet, the bark of official magnolia indentification by TLC；(3) check：Inspection including granularity, appearance uniform degree, moisture, content uniformity and microbial limit；(4) assay：Assay including ginsenoside Rg1.By above method, facial paralysis quality standard just scattered again can be made, so as to realize, to facial paralysis quality testing just scattered again, the experiment proved that, in this way for standard detection facial paralysis is just dissipating again, can be very good to ensure the stability of preparation, so as to ensure its curative effect.
Description
Technical field
The present invention relates to technical field of Chinese medicine, and in particular to facial paralysis quality determining method just scattered again.
Background technology
Facial paralysis is a kind of acute peripheral facial paralysis caused by the nonsuppurative inflammation of facial nerve.It is mainly shown as patient facial region
Expression myoparalysis, i.e. distortion of commissure, the category traditional Chinese medical science mouthful out-of-the-way (apoplex involving the channels and collaterals card).《Interior warp》Middle title mouth fish sticking its mouth out of the water, mouth it is out-of-the-way, and think facial paralysis
The mainly lesion of the stomach channel of foot-Yang-ming.It is bright《Jing Yue's complete work miliaria wind》Point out：" mouth eye fish sticking its mouth out of the water tiltedly have distinguishing for fever and chills ... but vim and vigour
Without losing, though then heat may not muscular atonia, though it is cold may not muscular contracture, also always understood by declining for vim and vigour." at present, this disease being thought middle medical circles more
By positive unsaturated vapor, interspaces of skin and muscles being loose, weakened defensive QI, collaterals being void and defenceless, ailment said due to cold or exposure is taken advantage of a weak point in opponent's defence the facial channels and collaterals of invasion and attack, facial Stomach Muscle Channel lose in
Foster, qi and blood numbness resistance is moistened, so that muscle is indulged to delay does not receive caused.But there are fever and chills not, there is face to suffer from cold factor, heat type facial paralysis more sympotoms caused by cold factors
The multifactor body overabundance of yang, cold-evil enter innerization heat, thermal resistance sun is bright, shaoyang meridians network, cause stagnant through vapour lock, and muscles along the regular meridians loses and support and send out in moistening.Facial paralysis
The treatment of early stage is very crucial, and whether early treatment is appropriate, directly affects recovery in the future.Hormone being given current early treatment more
To mitigate the compression of facial nerve oedema, slow down facial nerve denaturation.Early stage anemopyretic patient is more with infection, so antiviral, antibacterial
The use of element is also very necessary.External treatment of tcm treatment bell paralysis is evident in efficacy, and most researchers are matched somebody with somebody
Close acupuncture.
Peripheral facial paralysis acute stage, is most commonly seen in clinic, while acute stage is also when treating the gold of peripheral facial paralysis
Section, focuses on the treatment of this phase and nurses, and can play the curative effect got half the result with twice the effort.Using Chinese medicine external compound preparation, clinically merge
Acupuncture treatment, is a feasible program for treating peripheral facial paralysis.This treatment method can make the direct skin permeation of medicine, drug effect
Through focus, can promote Doppler flow mapping to set up, and mitigate local inflammation and ooze out and oedema, improve neural surrounding microcirculation, with rush
Enter regional flow, improve neurotrophic effect.With instant effect, short treating period, effect be good, advantage without side reaction.
Facial paralysis is just dissipating prescription and is being made up of pseudo-ginseng, prepared RADIX ET RHIZOMA RHEI, Chinese violet, the bark of official magnolia, the taste drug matching of borneol 5 again, is Kweiyang
The second affiliated hospital of college of traditional Chinese medicine Cai Wei deputy director doctor is formed for treating according to theory of traditional Chinese medical science and clinical experience aggegation for many years
Peripheral facial paralysis acute stage and the pure Chinese medicine compound external-use preparation of partial gall patient.Its composition medicine disappears with anti-inflammatory respectively
Effect of each side such as swollen, suppression inflammatory oozes out, antibacterial, analgesia, reduction capillary permeability, promotion organization wound repair.
Clinically merge acupuncture treatment to also indicate that, pain is effective after facial paralysis is just dissipating to improving ear again, and its possible mechanism is inflammation and pain
Being proportionate property, is by improving patient's local pain, the non-specific inflammatory symptoms of facial neuritis is effectively controlled.But mesh
The preceding quality determining method being applicable without the medicine, it is difficult to ensure the stability and curative effect of preparation.
The content of the invention
It is an object of the invention to provide the quality determining method that facial paralysis is just scattered again, to overcome the deficiencies in the prior art.
The technical scheme is that such：
Facial paralysis quality determining method just scattered again, the facial paralysis just dissipates be prepared again：By 5~15 parts of pseudo-ginseng, ripe big
Yellow 5~15 parts, 10~20 parts of Chinese violet, 5~15 parts of the bark of official magnolia, 0.3~1 part of borneol assort, in addition to borneol, pseudo-ginseng, prepared RADIX ET RHIZOMA RHEI,
This four traditional Chinese medicine material of Chinese violet magnolia obovata was ground into powder through 60 DEG C of drying under reduced pressure 3 hours；Borneol is finely ground, with above-mentioned powder
Facing-up, sieving, mixing, packing is obtained final product；
Facial paralysis quality determining method just scattered again includes following several：
(1) proterties：Khaki powder；Gas is pungent, bitter；
(2) differentiate：Including pseudo-ginseng, prepared RADIX ET RHIZOMA RHEI, Chinese violet, the bark of official magnolia indentification by TLC；
(3) check：Inspection including granularity, appearance uniform degree, moisture, content uniformity and microbial limit；
(4) assay：Assay including ginsenoside Rg1.
Wherein, the TLC Identification of pseudo-ginseng comprises the following steps：
Need testing solution, negative control solution, control medicinal material solution and reference substance solution are prepared respectively；According to thin-layered chromatography
Experiment, draws need testing solution, negative control solution, control medicinal material solution and reference substance solution point in same silica gel g thin-layer plate
On, with chloroform-acetate-methanol-water (15：40：22：10) 10 DEG C of lower floor's solution arranged below are solvent, exhibition
Open, take out, dry, spray with ethanol solution of sulfuric acid, be heated to spot development clear；
In test sample chromatogram, on position corresponding with control medicinal material and reference substance chromatogram, show the fluorescent spot of same color
Point, on the negative sample chromatogram relevant position for lacking pseudo-ginseng, without this spot.
Further, the TLC Identification of prepared RADIX ET RHIZOMA RHEI comprises the following steps：
Need testing solution, negative control solution and control medicinal material solution are prepared as respectively；According to thin-layered chromatography experiment, difference
Control medicinal material solution, negative control solution and need testing solution are taken, is put on same silica gel g thin-layer plate, with n-hexane-acetic acid second
Ester-formic acid (27：10：2.4) for solvent launches, take out, dry, inspected under 365nm ultraviolet lamps；
In test sample chromatogram, there is same color spot with position with control medicinal material, negative control is noiseless.
Further, the TLC Identification of Chinese violet comprises the following steps：
Need testing solution, negative control solution and control medicinal material solution are prepared respectively；According to thin-layered chromatography experiment, draw and supply
Test sample solution, negative control solution and control medicinal material solution, put on same silica gel g thin-layer plate, with toluene-acetic acid second respectively
Ester-formic acid (5：3：1) upper solution is solvent, is launched, and is taken out, and is dried, and is placed under 365nm ultraviolet lamps and inspects；
In test sample chromatogram, on position corresponding with control medicinal material chromatogram, show the fluorescence spot of same color, it is negative right
According to noiseless；
Further, the TLC Identification of the bark of official magnolia comprises the following steps：
Need testing solution, negative control solution and control medicinal material solution are prepared respectively；According to thin-layered chromatography, draw supply respectively
Test sample solution, negative control solution and control medicinal material solution, put on same silica gel g thin-layer plate, with petroleum ether (60~90 respectively
DEG C)-acetic ether-methanoic acid (8.5：1.5：0.2) it is solvent, launches, take out, dry, spray is with vanillin-sulfuric acid solution, heating
It is clear to spot development；
In test sample chromatogram, on position corresponding with reference substance chromatogram, show same color spot, and negative control without dry
Disturb.
Further, facial paralysis limit test of microbe just scattered again is carried out using Plating.
Further, the assay of the ginsenoside Rg1 comprises the following steps：
Need testing solution is prepared with this product, with ginsenoside Rg1Reference substance solution is prepared, reference substance solution is drawn and is supplied to try
Product solution injection liquid chromatograph is measured, and chromatographic condition is：With Aglient ZORBAX SB-C8(150 × 4.6mm, 5 μ
M) it is chromatographic column；With acetonitrile as mobile phase A, with water as Mobile phase B, gradient elution is carried out；Flow velocity is 1ml/min；30 DEG C of column temperature；
Detection wavelength is 203nm；Gradient elution is provided as follows：
Mobile phase A：0~20 minute：18%；20~30 minutes：18 → 19%；
Mobile phase B：0~20 minute：82%；20~30 minutes：82 → 81%.
Technique effect of the invention is as follows：
By above method, facial paralysis quality standard just scattered again can be made, so as to realize to facial paralysis matter just scattered again
Amount detection, the experiment proved that, in this way for standard detection facial paralysis is just dissipating again, can be very good to ensure the stability of preparation, from
And ensure its curative effect.
Brief description of the drawings
Fig. 1 is the process chart of preparation method of the invention；
Fig. 2 is the thin layer discriminating figure of pseudo-ginseng of the invention；In figure, 1, pseudo-ginseng control medicinal material；2nd, notoginsenoside R and ginseng
Saponin(e Rg1 and ginsenoside Rb1's mixing reference substance；3~5, facial paralysis just dissipates test sample (lot number again：20160311,20160312,
20160313)；6th, negative test sample (scarce pseudo-ginseng)；
Fig. 3 is the thin layer discriminating figure of prepared RADIX ET RHIZOMA RHEI；In figure：1st, prepared RADIX ET RHIZOMA RHEI control medicinal material；2~4, facial paralysis just dissipates test sample again
(lot number：20160311,20160312,20160313)；5th, negative test sample (lacking prepared RADIX ET RHIZOMA RHEI medicinal material)；
Fig. 4 is the thin layer discriminating figure of Chinese violet；In figure, 1, Chinese violet control medicinal material；2~4, facial paralysis is just being dissipated for examination again
Product (lot number：20160311,20160312,20160313)；5th, negative test sample (lacking Chinese violet medicinal material)；
Fig. 5 is the thin layer discriminating figure of the bark of official magnolia；In figure, 1, bark of official magnolia control medicinal material；2~4, facial paralysis just dissipates test sample (lot number again：
20160311,20160312,20160313)；5th, negative test sample (scarce magnolia medicament)；
Fig. 6 is the thin layer discriminating figure one of the bark of official magnolia；In figure, 1, borneol control medicinal material；2nd, facial paralysis just dissipates test sample (lot number again：
20160501)；3rd, negative test sample (lacking borneol medicinal material)；
Fig. 7 is the thin layer discriminating figure two of the bark of official magnolia；In figure, 1, borneol control medicinal material；2nd, facial paralysis just dissipates test sample (lot number again：
20160501)；3rd, negative test sample (lacking borneol medicinal material).
Specific embodiment
The present invention is described in further detail with reference to the accompanying drawings and examples, but protection scope of the present invention is not received
Any limitation of specific embodiment, but be defined in the claims.
Embodiment 1：
1st, prescription composition：Pseudo-ginseng 10g prepared RADIX ET RHIZOMA RHEI 10g Chinese violet 15g bark of official magnolia 10g borneols 0.5g.
2nd, preparation method：Technological process as shown in Figure 1, the above five tastes are assorted by 23 times of amounts of prescription, in addition to borneol,
The four traditional Chinese medicine such as pseudo-ginseng, prepared RADIX ET RHIZOMA RHEI material was ground into most fine powder through 60 DEG C of drying under reduced pressure 3 hours；Borneol is finely ground, match somebody with somebody with above-mentioned powder
Grind, sieve, mixing, packing is obtained final product.Loading amount standard：6g/ bags.
3rd, indication：It is clearing heat for detumescence, promoting blood circulation and removing obstruction in channels.For peripheral facial paralysis acute stage and partial gall patient.
4th, usage and dosage：External application, according to the state of an illness, external application, apply part acupuncture point, per cave is mixed well from vaseline, grease etc.
One patch, once a day, January is 1 course for the treatment of.Needed that the course for the treatment of can be repeated according to the state of an illness.
5th, check：According under powder pertinent regulations (《Chinese Pharmacopoeia》Four general rules 0115 of version in 2015) examined
Look into.Granularity, appearance uniform degree, moisture, content uniformity, microbial limit are checked respectively for, regulation should be met.
5.1st, granularity：(general rule 0115) is determined under powder " granularity " item, should meet regulation.
5.2nd, appearance uniform degree is determined according to (general rule 0115) under powder " appearance uniform degree " item, should meet regulation.
5.3rd, moisture：According to lower second method of aquametry (《Chinese Pharmacopoeia》Four general rules 0832 of version in 2015) carry out
Determine, moisture must not cross 9.0%.
5.4th, content uniformity：10 bags of this product is taken, (general rule 0115) checks that loading amount is poor in accordance with the law under powder " content uniformity " item
Different limit should must not be more than 2 bags, and must not have 1 bag of 1 times of overrun within ± 7% beyond content uniformity limit.
Experimental example 1：
Facial paralysis quality determining method just scattered again：
1 proterties：Three batches of samples of pilot scale are khaki powder；Gas is pungent, bitter.
2 thin layers differentiate：
The thin-layer chromatography research of 2.1 pseudo-ginseng
This product 2g, plus 5ml water are taken, is stirred evenly, add water the n-butanol 50ml of saturation, ultrasonically treated 1 hour, filtration, filtrate
Extracted with the water of 120ml n-butanol saturations, divide and take n-butanol layer, water bath method, residue 1ml methyl alcohol dissolves, used as test sample
Solution.The negative simulation preparation 2g of pseudo-ginseng is taken, negative control solution is prepared with method.Separately take pseudo-ginseng powder 0.5g, same to legal system
Into control medicinal material solution.Ginsenoside Rg is weighed again1Reference substance, ginsenoside Rb1Reference substance and Panax Notoginseng saponin R1Reference substance is fitted
Amount, is made solution of every 1ml containing 0.5mg, as reference substance solution of methyl alcohol respectively.According to thin-layered chromatography (《Chinese Pharmacopoeia》
Four general rules 0502 of version in 2015) experiment, above-mentioned each 5 μ l of four kinds of solution are drawn, put respectively on same silica gel g thin-layer plate, with
Chloroform-acetate-methanol-water (15：40：22：10) 10 DEG C of lower floor's solution arranged below are solvent, are launched, and are taken
Go out, dry, spray with 10% ethanol solution of sulfuric acid, be heated to spot development at 105 DEG C clear.In test sample chromatogram, with it is right
According on medicinal material and the corresponding position of reference substance chromatogram, show the spot of same color, lack the negative sample chromatogram phase of pseudo-ginseng
Answer on position, without this spot (see Fig. 2).
The thin-layer chromatography research of 2.2 prepared RADIX ET RHIZOMA RHEIs
This product 2g, plus methyl alcohol 15ml are taken, ultrasonic extraction 20min is filtered, and filtrate is concentrated into 1ml, used as need testing solution.
The negative simulation preparation 2g of scarce prepared RADIX ET RHIZOMA RHEI is taken, negative control solution is prepared with method.Prepared RADIX ET RHIZOMA RHEI control medicinal material powder 5g separately is taken, plus
The straight fire refluxing extraction 1h of 40ml water, filtrate water-bath Back stroke is done, and residue adds methyl alcohol 10ml to be transferred in conical flask, ultrasonic extraction 10min,
Filtrate is concentrated into 1ml, used as control medicinal material solution.According to thin-layered chromatography (《Chinese Pharmacopoeia》Four general rules 0502 of version in 2015) examination
Test, the μ l of control medicinal material solution 3, negative control solution, each 2 μ l of compound test solution are taken respectively, put in same silica gel g thin-layer plate
On, with n-hexane-ethyl acetate-formic acid (27：10：2.4) for solvent launches, take out, dry, under 365nm ultraviolet lamps
Inspect.In test sample chromatogram, there is same color spot with position with control medicinal material, negative control is noiseless (see Fig. 3).
The thin-layer chromatography research of 2.3 Chinese violets
This product 2g, plus methyl alcohol 20ml dissolvings are taken, ultrasonically treated 30min, filtration, filtrate is evaporated, and residue adds pure water 10ml, stirs
Mixing makes dissolving, filtration, and filtrate is evaporated, and residue adds the ethyl acetate 1ml to make dissolving, used as need testing solution.Take scarce Chinese violet
Feminine gender simulation preparation 2g, negative control solution is prepared with method.Chinese violet control medicinal material 1.0g separately is taken, control medicinal material is made in the same way of
Solution.According to thin-layered chromatography (《Chinese Pharmacopoeia》Four general rules 0502 of version in 2015) experiment, above-mentioned each 3 μ l of three kinds of solution are drawn,
Put respectively on same silica gel g thin-layer plate, with toluene-ethyl acetate-formic acid (5：3：1) upper solution is solvent, is launched,
Take out, dry, be placed under uviol lamp (365nm) and inspect.In test sample chromatogram, on position corresponding with control medicinal material chromatogram,
The fluorescence spot of aobvious same color, negative control is noiseless (see Fig. 4).
The thin-layer chromatography research of 2.4 barks of official magnolia
Test sample 2g is taken, the negative control sample 2g prepared by formula rate is taken, methyl alcohol 15ml, ultrasonic 30min is added respectively,
Filtration, filtrate is respectively as need testing solution and negative control solution.Bark of official magnolia control medicinal material powder 0.5g, plus 5ml methyl alcohol separately are taken,
It is made in the same way of control medicinal material solution；According to thin-layered chromatography (《Chinese Pharmacopoeia》Four general rules 0502 of version in 2015) experiment, inhale respectively
Each 2 μ l of above-mentioned need testing solution, negative control solution, the μ l of control medicinal material solution 5 are taken, are put respectively on same silica gel g thin-layer plate,
With petroleum ether (60~90 DEG C)-acetic ether-methanoic acid (8.5：1.5：0.2) it is solvent, launches, take out, dry, sprays with 1%
Vanillin-sulfuric acid solution, is heated to spot development clear at 100 DEG C.In test sample chromatogram, in position corresponding with reference substance chromatogram
Put, show same color spot, and negative control is noiseless (see Fig. 5).
The thin-layer chromatography research of 2.5 borneols
With reference to " borneol in TLC, GC method detection storax capsule for treating coronary heart disease "[14]In to borneol thin-layer chromatography study：Take this product
1g, adds ethyl acetate 10ml, and extraction takes acetic acid ethyl fluid, as need testing solution.The negative simulation reagent 1g of scarce borneol is taken,
Negative controls are prepared with method.It is another to take borneol control medicinal material 1g, plus it is the solution of 2mg/ml that ethyl acetate is made concentration, as right
According to product solution.According to thin-layered chromatography (《Chinese Pharmacopoeia》Four general rules 0502 of version in 2015) experiment, draw above-mentioned three kinds of solution each 2
μ l, put on silica G thin web, with petroleum ether (30~60 DEG C)-ethyl acetate (9 respectively：1) it is solvent, launches, takes out,
Dry, spray with phosphomolybdic acid test solution, it is clear that hot blast is blown to spot development.In test sample chromatogram, corresponding with control medicinal material chromatogram
On position, without corresponding spot (see Fig. 6).To borneol in reference " compound inflammation-diminishing dissipates the indentification by TLC of middle borneol and turmeric "
Thin-layer chromatography is studied：This product 1g is taken, chloroform 10ml extractions are added, chloroform liquid is taken, as need testing solution.Take scarce ice
The negative simulation reagent 1g of piece, negative controls are prepared with method.It is another to take borneol control medicinal material, plus it is 1mg/ that ethyl acetate is made concentration
The solution of ml, as reference substance solution.According to thin-layered chromatography (《Chinese Pharmacopoeia》Four general rules 0502 of version in 2015) experiment, draw
Above-mentioned each 2 μ l of three kinds of solution, put on silica gel g thin-layer plate, with cyclohexane-ethyl acetate (17 respectively：3) it is solvent, launches,
Take out, dry, spray with phosphomolybdic acid test solution, it is clear that hot blast is blown to spot development.In test sample chromatogram with control medicinal material chromatogram phase
On the position answered, without corresponding spot (see Fig. 7).Therefore the Qualitive test of borneol excludes quality determining method of the invention.
Experimental example 2：Microbial decolorization
1st, the preparation of test liquid：This product 10ml is taken, is added and is no more than 45 DEG C of PH7.0 sterile NaCls-peptone dilutions
It is stirring while adding to 100ml, test sample is fully mixed, obtain final product 1:10 test liquid.
2nd, microorganism count method：The total counting number of aerobic bacteria：Take 1:10 1 ware of test liquid 1ml dispensings, 1ml/ wares are pressed《China
Pharmacopeia》2015 editions four non-sterile product limit test of microbe：Plating is carried out under microorganism count method (general rule 1105) item
Colony counting.
The total counting number of yeast and mold：Take 1:10 2 wares of test liquid 2ml dispensings, 1ml/ wares are pressed《Chinese Pharmacopoeia》2015
Four non-sterile product limit test of microbe of version：Plating in microorganism count method (general rule 1105) carries out colony counting.
3rd, Control bacteria examination：
Staphylococcus aureus：Take 1:10 test liquids according to《Chinese Pharmacopoeia》2015 editions four non-sterile product microorganism limits
Degree is checked：Corresponding Control bacteria examination method is carried out under Control bacteria examination method (general rule 1106).
Pseudomonas aeruginosa：Take 1:10 test liquids according to《Chinese Pharmacopoeia》2015 editions four non-sterile product microbial limits
Check：Corresponding Control bacteria examination method is carried out under Control bacteria examination method (general rule 1106).
Microbial limit test of drugs method applicability test report
Culture medium, diluent and source：
0.9% sterile NaCl-peptone buffer agent, pancreas junket soya peptone agar, Sabouraud's dextrose agar, pancreas junket soya peptone
Fluid nutrient medium, Mai Kangkai fluid nutrient mediums, maconkey agar culture medium etc..(Shanghai Sheng Si biochemical technologies Co., Ltd produces,
Press《Chinese Pharmacopoeia》2015 editions relevant regulations are prepared and sterilized).
Strain and source：
Above strain is National Institute for Food and Drugs Control and derives from strain.
Laboratory apparatus：Autoclave sterilizer, electronic balance (1/10th), toilet's clean work station, colony counting
Device etc..
As a result：Applicability is recorded and result is as follows：
1st, aerobic bacteria, mould and saccharomycete sum method of counting Selection experiment the results are shown in Table 1；
2nd, aerobic bacteria, mould and saccharomycete sum method of counting checking recovery test are shown in Table 2-4 (subordinate list records 1-3)；
3rd, bacterium --- the result of staphylococcus aureus inspection method see the table below 5 for control；
4th, bacterium --- the result of pseudomonas aeruginosa inspection method see the table below 6 for control；
The aerobic bacteria of table 1, mould and saccharomycete sum method of counting Selection experiment result
Remarks：" --- " represents and does not do this.
Conclusion：
1、1:10 test liquid uses Plating (1ml/ wares) EHEC, Candida albicans, the rate of recovery of aspergillus niger
More than 70% can be reached；1:10 test liquid can reach 70% using the rate of recovery of Plating (0.5ml/ wares) bacillus subtilis
More than, 1:10 test liquid can reach more than 70% using the rate of recovery of Plating (0.2ml/ wares) staphylococcus aureus.
2nd, facial paralysis just dissipates again has bacteriostatic active ingredients (such as：Chinese violet, bark of official magnolia etc.), therefore carrying out microorganism checking
When, there are obvious bacteriostasis, especially the inhibition to staphylococcus aureus is obvious, next to that to withered grass gemma
Bacillus has certain inhibitory action, so carried out using Plating, and effect of the medicine to bacillus subtilis is not it is obvious that
Take conventional method.According to the result, verification operation step is considered, it is final to determine to use Plating (1:10 for examination
Liquid 1ml, 5 plates of dispensing) limit test of microbe just scattered again to carry out facial paralysis.
The aerobic bacteria of table 2, mould and saccharomycete sum method of counting checking recovery test record 1
Note：Test group：Test liquid+experiment bacterium solution；Test sample control group：Test liquid+dilution；Bacterium solution group：Dilution+examination
Test bacterium solution.
The aerobic bacteria of table 3, mould and saccharomycete sum method of counting checking recovery test record 2
The aerobic bacteria of table 4, mould and saccharomycete sum method of counting checking recovery test record 3
The checking test record of the staphylococcus aureus inspection method of table 5
Remarks：In mannitol sodium chloride plates："+" is labeled with colonies typical growth；"-" indicates asepsis growth.
In coagulase test of blood plasma："+" is labeled with the clotting of plasma；"-" sign blood plasma does not solidify.
" --- " represents and does not do this.
The checking test record of the pseudomonas aeruginosa inspection method of table 6
Remarks：In mannitol sodium chloride plates："+" is labeled with colonies typical growth；"-" indicates asepsis growth.
In oxidase test：There is the change of pink-aubergine in culture on "+" sign paper；Trained on "-" sign paper
Support thing nondiscolouring or only show pink and change.
In pyo experiment：There is pink discolouration reaction in "+" sign；"-" sign occurs without pink.
" --- " represents and does not do this.
Conclusion：
Through this verification experimental verification, facial paralysis Aerobic Count just scattered again can be pressed《Chinese Pharmacopoeia》2015 editions four general rules 1105
Lower Plating (1:10 test liquids, 0.2ml/ wares) counted；Mould and the total counting number of saccharomycete can be pressed《Chinese Pharmacopoeia》2015
Version 1105 lower Platings of general rule (take 1:10 2 wares of test liquid 2ml dispensings, 1.0ml/ wares) count；Golden yellow Portugal in control bacterium
The inspection of grape coccus and pseudomonas aeruginosa can be pressed《Chinese Pharmacopoeia》The conventional method specified under 2015 editions general rules 1106 is examined
Look into.
Experimental example 3：Assay
Ginsenoside Rg1 according to high performance liquid chromatography (《Chinese Pharmacopoeia》Four general rules 0512 of version in 2015) determine.
1. instrument and reagent
Instrument：The high performance liquid chromatographs of Agilent 1260；Plum Teller-support benefit AE electronic analytical balances (METTLER
The a ten thousandths of TOLEDO ten).
Reagent：Acetonitrile [chromatographically pure, the U.S. world (TEDIA) Co., Ltd]；Water (Wahaha drinking pure water, Kweiyang baby
Heartily Food Co., Ltd's manufacture).
Reference substance：(for assay, in terms of 91.7%, lot number is content ginsenoside Rg1's reference substance：110703-
201530), purchased from Chinese food drug assay research institute.
Sample：Facial paralysis just dissipates (lot number again：20160501 20160502 20160503).
2. prepared by reference substance solution
The preparation of reference substance solution：Precision weighs ginsenoside Rg1 reference substance 4.536mg, plus methyl alcohol is made every 1ml containing people
The solution of ginseng saponin(e Rg1 0.416mg, obtains final product.
3. the selection of chromatographic condition：
Carrying out ginsenoside Rg1During chromatography condition, bibliography has carried out chromatographic column, mobile phase and column temperature
Screening.
The selection of 3.1 chromatographic columns
Different chromatographic columns is separated to chemical composition and had a certain impact, and Diamonsil Plus C18 colors have been investigated herein
Spectrum post (250 × 4.6mm, 5 μm)；Ultimate XB-C18 chromatographic columns (250 × 4.6mm, 5 μm)；Aglient ZORBAX SB-
C18(250 × 4.6mm, 5 μm) and Aglient ZORBAX SB-C8(150 × 4.6mm, 5 μm) four kinds of chromatographic column, the results are shown in Table 7.
The ginsenoside Rg of table 71Chromatogram column condition selects table
It is compared by chromatogram under the conditions of different chromatographic columns, as a result shows Ultimate XB-C18Before chromatographic column peak
Prolong, symmetry is poor, separating degree is low；Diamonsil plus C18 chromatographic column peak stretchings, peak shape is poor；Agilent Zorbax SB-
C18Chromatographic column peak trails, inferior separating effect；Agilent Zorbax SB-C8Preferably, separating degree is higher for chromatographic column peak shape, therefore
Determine Agilent Zorbax SB-C8(150 × 4.6mm, 5 μm) chromatographic column is experiment post.
The investigation of 3.2 mobile phases
Three kinds of different elution systems are investigated, 8-10 is the results are shown in Table.
The elution system one of table 8
The elution system two of table 9
The elution system three of table 10
By comparing the chromatographic peak of three of the above difference elution system, the wherein ginsenoside Rg of elution system one1With other
Component peaks are not kept completely separate, inferior separating effect；The chromatographic peak of elution system two is separated preferably, and peak shape is sharper；The ginseng of elution system three
Saponin(e Rg1It is not kept completely separate with other components peak, and feminine gender has interference, inferior separating effect.It is thus determined that elution system two is stream
Dynamic phase condition.
The investigation of 3.3 column temperatures
Investigated respectively 25 DEG C, 30 DEG C, 35 DEG C when chromatographic isolation effect.
Result shows, when column temperature is 25 DEG C, ginsenoside Rg1It is not kept completely separate with other components peak, inferior separating effect；Post
Temperature is 30 DEG C, 35 DEG C it is unobvious on the influence of the separating effect of chromatographic peak, it is contemplated that situations such as room temperature, selection column temperature is 30 DEG C.
To sum up, ginsenoside Rg is determined1Chromatographic condition be Agilent Zorbax SB-C8(150 × 4.6mm, 5 μm) color
Spectrum post；Acetonitrile-water gradient：0~20min (18:82), 21~30min (19:81)；Flow velocity：1ml/min；Column temperature：30℃；
Detection wavelength：203nm；Analysis time：30min；Sample size：10μl.Number of theoretical plate presses ginsenoside Rg1Calculating should be not less than
4000。
Certainly, it is more than the concrete application example of invention, the present invention also has other implementation methods, all use is equally replaced
Change or equivalent transformation formed technical scheme, all fall within protection domain of the presently claimed invention.
Claims (7)
1. the quality determining method that facial paralysis is just dissipating again, it is characterised in that：The facial paralysis just dissipates be prepared again：By pseudo-ginseng 5~
15 parts, 5~15 parts of prepared RADIX ET RHIZOMA RHEI, 10~20 parts of Chinese violet, 5~15 parts of the bark of official magnolia, 0.3~1 part of borneol assort, in addition to borneol, three
7th, this four traditional Chinese medicine material of prepared RADIX ET RHIZOMA RHEI, Chinese violet magnolia obovata was ground into powder through 60 DEG C of drying under reduced pressure 3 hours；Borneol is finely ground,
With above-mentioned powder facing-up, sieve, mixing, packing is obtained final product；
Facial paralysis quality determining method just scattered again includes following several：
(1) proterties：Khaki powder；Gas is pungent, bitter；
(2) differentiate：Including pseudo-ginseng, prepared RADIX ET RHIZOMA RHEI, Chinese violet, the bark of official magnolia indentification by TLC；
(3) check：Inspection including granularity, appearance uniform degree, moisture, content uniformity and microbial limit；
(4) assay：Assay including ginsenoside Rg1.
2. the quality determining method that facial paralysis according to claim 1 is just dissipating again, it is characterised in that：The thin-layer chromatography mirror of pseudo-ginseng
Other method comprises the following steps：
Need testing solution, negative control solution, control medicinal material solution and reference substance solution are prepared respectively；According to thin-layered chromatography examination
Test, draw need testing solution, negative control solution, control medicinal material solution and reference substance solution point on same silica gel g thin-layer plate,
With chloroform-acetate-methanol-water (15：40：22：10) 10 DEG C of lower floor's solution arranged below are solvent, are launched,
Take out, dry, spray with ethanol solution of sulfuric acid, be heated to spot development clear；
In test sample chromatogram, on position corresponding with control medicinal material and reference substance chromatogram, show the fluorescence spot of same color,
Lack on the negative sample chromatogram relevant position of pseudo-ginseng, without this spot.
3. the quality determining method that facial paralysis according to claim 1 is just dissipating again, it is characterised in that：The thin-layer chromatography of prepared RADIX ET RHIZOMA RHEI
Discrimination method comprises the following steps：
Need testing solution, negative control solution and control medicinal material solution are prepared as respectively；According to thin-layered chromatography experiment, it is right to take respectively
According to medicinal material solution, negative control solution and need testing solution, put on same silica gel g thin-layer plate, with n-hexane-ethyl acetate-
Formic acid (27：10：2.4) for solvent launches, take out, dry, inspected under 365nm ultraviolet lamps；
In test sample chromatogram, there is same color spot with position with control medicinal material, negative control is noiseless.
4. the quality determining method that facial paralysis according to claim 1 is just dissipating again, it is characterised in that：The thin layer color of Chinese violet
Spectrum discrimination method comprises the following steps：
Need testing solution, negative control solution and control medicinal material solution are prepared respectively；According to thin-layered chromatography experiment, test sample is drawn
Solution, negative control solution and control medicinal material solution, put on same silica gel g thin-layer plate, with toluene-ethyl acetate-first respectively
Acid (5：3：1) upper solution is solvent, is launched, and is taken out, and is dried, and is placed under 365nm ultraviolet lamps and inspects；
In test sample chromatogram, on position corresponding with control medicinal material chromatogram, show same color fluorescence spot, negative control without
Interference.
5. the quality determining method that facial paralysis according to claim 1 is just dissipating again, it is characterised in that：The thin-layer chromatography mirror of the bark of official magnolia
Other method comprises the following steps：
Need testing solution, negative control solution and control medicinal material solution are prepared respectively；According to thin-layered chromatography, test sample is drawn respectively
Solution, negative control solution and control medicinal material solution, put on same silica gel g thin-layer plate respectively, with petroleum ether (60~90 DEG C)-
Acetic ether-methanoic acid (8.5：1.5：0.2) it is solvent, launches, take out, dry, spray with vanillin-sulfuric acid solution, is heated to spot
Point colour developing is clear；
In test sample chromatogram, on position corresponding with reference substance chromatogram, show same color spot, and negative control is noiseless.
6. the quality determining method that facial paralysis according to claim 1 is just dissipating again, it is characterised in that：Carried out using Plating
Facial paralysis limit test of microbe just scattered again.
7. the quality determining method that facial paralysis according to claim 1 is just dissipating again, it is characterised in that：The ginsenoside Rg1
Assay comprise the following steps：
Need testing solution is prepared with this product, with ginsenoside Rg1Reference substance solution is prepared, reference substance solution is drawn molten with test sample
Liquid injection liquid chromatograph is measured, and chromatographic condition is：With Aglient ZORBAX SB-C8(150 × 4.6mm, 5 μm) is
Chromatographic column；With acetonitrile as mobile phase A, with water as Mobile phase B, gradient elution is carried out；Flow velocity is 1ml/min；30 DEG C of column temperature；Detection
Wavelength is 203nm；Gradient elution is provided as follows：
Mobile phase A：0~20 minute：18%；20~30 minutes：18 → 19%；
Mobile phase B：0~20 minute：82%；20~30 minutes：82 → 81%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710132017.6A CN106872634A (en) | 2017-03-07 | 2017-03-07 | Facial paralysis quality determining method just scattered again |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710132017.6A CN106872634A (en) | 2017-03-07 | 2017-03-07 | Facial paralysis quality determining method just scattered again |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106872634A true CN106872634A (en) | 2017-06-20 |
Family
ID=59170638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710132017.6A Pending CN106872634A (en) | 2017-03-07 | 2017-03-07 | Facial paralysis quality determining method just scattered again |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106872634A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1824244A (en) * | 2005-12-29 | 2006-08-30 | 贵州益佰制药股份有限公司 | Quelity control method of Chinese medicinal preparation for hepatatitis toxin resolving |
| CN101115493A (en) * | 2005-08-12 | 2008-01-30 | 河乃建仁 | Agent for hair growth |
| CN101698034A (en) * | 2009-11-05 | 2010-04-28 | 广州中一药业有限公司 | Method for controlling quality of modified inspirex extract |
| CN102068504A (en) * | 2009-11-19 | 2011-05-25 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Quality control method of phlegm-eliminating pill for treating pyrophlegm stagnation and dry feces |
| CN105548406A (en) * | 2016-01-20 | 2016-05-04 | 李兴惠 | Quality control method for Huju hepatitis B preparation and preparation |
-
2017
- 2017-03-07 CN CN201710132017.6A patent/CN106872634A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101115493A (en) * | 2005-08-12 | 2008-01-30 | 河乃建仁 | Agent for hair growth |
| CN1824244A (en) * | 2005-12-29 | 2006-08-30 | 贵州益佰制药股份有限公司 | Quelity control method of Chinese medicinal preparation for hepatatitis toxin resolving |
| CN101698034A (en) * | 2009-11-05 | 2010-04-28 | 广州中一药业有限公司 | Method for controlling quality of modified inspirex extract |
| CN102068504A (en) * | 2009-11-19 | 2011-05-25 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Quality control method of phlegm-eliminating pill for treating pyrophlegm stagnation and dry feces |
| CN105548406A (en) * | 2016-01-20 | 2016-05-04 | 李兴惠 | Quality control method for Huju hepatitis B preparation and preparation |
Non-Patent Citations (4)
| Title |
|---|
| 国家药典委员会 编: "《中华人民共和国药典 2010年版 一部》", 31 January 2010 * |
| 张振秋 等主编: "《药物分析》", 31 January 2016 * |
| 张瑞 等: "泡沫浮选-固相提取分离富集三七提取液中的人参皂苷", 《分析化学》 * |
| 蔡伟 等: "面瘫复正贴膏与针刺并用对周围性面瘫（急性期）患者临床疗效的观察", 《中医临床研究》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhong et al. | Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases | |
| Liu et al. | Potential antidepressant properties of Radix polygalae (Yuan Zhi) | |
| Lau et al. | Synergistic interaction between Astragali Radix and Rehmanniae Radix in a Chinese herbal formula to promote diabetic wound healing | |
| CN105477166B (en) | A kind of preparation method and its method of quality control of duhuo jisheng decoction granule | |
| CN101259172B (en) | Chinese medicinal composition for treating acne, preparation and application thereof | |
| Chen et al. | Saikosaponin a and saikosaponin d inhibit proliferation and migratory activity of rat HSC-T6 cells | |
| CN105477006A (en) | Stomatitis clearing active component group and fingerprint characteristic spectrum constructing and quality detecting method for same | |
| Qiu et al. | The effect of Chaihu-Shugan-San and its components on the expression of ERK5 in the hippocampus of depressed rats | |
| Yue et al. | Screening for anti‐inflammatory and bronchorelaxant activities of 12 commonly used Chinese herbal medicines | |
| Lee et al. | Astragaloside II promotes intestinal epithelial repair by enhancing L-arginine uptake and activating the mTOR pathway | |
| CN101708274B (en) | Quality control method of pill preparation for treating chest impediment and cardialgia | |
| Zheng et al. | Effects of herbal drugs in Mahuang decoction and their main components on intestinal transport characteristics of Ephedra alkaloids evaluated by a Caco-2 cell monolayer model | |
| Zhan et al. | The sulfur-fumigation reduces chemical composition and biological properties of Angelicae sinensis radix | |
| Yan et al. | Chemical characterization and neuroprotective properties of copper nanoparticles green-synthesized by nigella sativa L. seed aqueous extract against methadone-induced cell death in adrenal phaeochromocytoma (PC12) cell line | |
| Bekara et al. | Evaluating the antidepressant Effect of Verbena officinalis L.(Vervain) aqueous extract in adult rats | |
| CN102426205B (en) | Detection method of thrombus sumalin capsules | |
| CN102353735B (en) | Quality detection method for Tongmai Tangyanming capsule | |
| Malathi et al. | Antioxidant activity of extract from the leaves of Tylophora asthmatica | |
| Ma et al. | Effects of traditional Chinese medicinal plants on anti-insulin resistance bioactivity of DXMS-induced insulin resistant HepG2 cells | |
| Nikolaou et al. | Accidental poisoning after ingestion of “aphrodisiac” berries: diagnosis by analytical toxicology | |
| CN101890087A (en) | Composition containing coptis root, rhubarb and baikal skullcap root | |
| CN107252465B (en) | Analysis method of traditional Chinese medicine composition for regulating allergic constitution | |
| Jäger et al. | Activity of a traditional South African epilepsy remedy in the GABA-benzodiazepine receptor assay | |
| CN109674866A (en) | A kind of anti-human primary gastrointestinal cancers pharmaceutical composition, preparation method and applications | |
| Gryszczynska et al. | Bioactive compounds determination in the callus and hydroalcoholic extracts from Salvia miltiorrhiza and Salvia przewalskii–Preliminary study on their anti-alcoholic activity effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170620 |
|
| RJ01 | Rejection of invention patent application after publication |